Welcome to AstraZeneca United States

We push the boundaries of science to deliver life-changing medicines

AZ&You Blog
 

Going green: Blazing a trail in sustainability

Leading a Revolution in Oncology by Starting With One

Living with Lupus: The Unique, Unpredictable Journey

Innovation, Partnership and Advocacy: How AstraZeneca is Working to Improve Life for Hyperkalemia Patients

By Tarek Rabah, AstraZeneca US Renal Cardio Vice President

Latest News from AstraZeneca US
 

IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial

IMFINZI combined with novel immunotherapies improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer

IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy

Follow AstraZeneca on Twitter and Facebook

Pascal Soriot calls for global cooperation in the fight against COVID-19 and climate change

COVID-19 Information Hub

BioPharmaceuticals

We want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. Our ambition is to stop the progress of these often degenerative, debilitating, and life-threatening conditions, achieve remission, and one day cure them.

Learn more

Oncology: Start with One

At AstraZeneca, we are leading a revolution in oncology to redefine cancer care for the millions of Americans living with cancer. It’s a lofty ambition. But we know that as with every great journey, the road always starts with one—one indication that can change the course of disease for a patient, one person living with cancer that benefits from our support services, one access barrier that we can help to overcome, one system to transform in partnership with the community—and then another, building from there until success is achieved. Click below to read more about this next chapter.

Learn more